{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.78","upperLimit":"6.22","value":"6.00"},{"groupId":"OG001","lowerLimit":"12.68","upperLimit":"13.60","value":"13.13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"236"},{"groupId":"OG001","value":"233"}],"units":"Participants"}],"description":"HRU is defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient. HRU is a key component to understand treatment costs and budget impact of new treatments from a provider perspective.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 300 mg azacitidine tablets once a day (QD) for the first 14 days of each 28-day treatment cycle until discontinuation, which includes the following reasons: disease relapse, withdrawal of consent, adverse events, participant became eligible for allogeneic bone marrow or stem cell transplantation during the treatment period, death, lost to follow-up, or protocol violation or until the end of the study.","id":"OG000","title":"Oral Azacitidine Plus Best Supportive Care"},{"description":"Participants received identically matching placebo tablets QD for the first 14 days of each 28-day treatment cycle until no longer receiving benefit, withdrawal of consent, disease relapse, adverse events, participant became eligible for allogeneic bone marrow or stem cell transplantation during the treatment period, lost to follow-up, or protocol violation or until the end of the study.","id":"OG001","title":"Placebo Plus Best Supportive Care"}],"paramType":"NUMBER","populationDescription":"Safety population includes all participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From day 1 (randomization) up to data cut off date of 06 August 2024; approximately 135.5 months","title":"Healthcare Resource Utilization (HRU): Number of Days Hospitalized Per Person-Year","type":"SECONDARY","unitOfMeasure":"Days per person-years"}